New drug vs. standard therapy for advanced HER2-positive colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new targeted drug called BL-M07D1 against standard chemotherapy options chosen by your doctor. It is for people with a specific type of advanced colorectal cancer (HER2 IHC3+) that has stopped responding to earlier chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer is advanced and has spread to other parts of your body.
- Your tumor tests as HER2 IHC3+ (a specific protein level).
- You have already tried oxaliplatin, fluorouracil, and irinotecan chemotherapy, and they no longer work.
- You are between 18 and 75 years old.
- You are able to carry out your daily activities with little to no help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
This trial tests a new drug called JSKN003 against other standard treatments for advanced colorectal cancer that has a specific marker called HER2. It's for people whose cancer has not responded to previous chemotherapy drugs.
This trial tests an injection called TQB2102 for people with advanced colorectal cancer that has a specific marker called HER2 IHC3+. If you have tried at least two standard treatments and they stopped working or caused side effects, this study may be an option.
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.